The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2026 | Findings from the State of the Nation report by the National Lung Cancer Audit
Lauren Dixon, MBChB, MRes, MRCS, London School of Hygiene & Tropical Medicine, London, UK, discusses the recent State of the Nation report published by the National Lung Cancer Audit, highlighting encouraging progress in lung cancer care in England and Wales, including increased diagnoses of early-stage disease and improved survival rates. Despite these advancements, challenges persist, such as prolonged waiting times and variable access to treatments, which require system-level solutions to increase capacity for diagnoses and curative intent treatment options. This interview took place at the 2026 British Thoracic Oncology Group (BTOG) congress in Edinburgh, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
The National Lung Cancer Organisation has recently published our State of the Nation report, and it shows some really encouraging progress for lung cancer care in England and Wales. Firstly, we’ve seen an increase in the number of patients diagnosed with early-stage disease, more than we’ve ever seen before...
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
The National Lung Cancer Organisation has recently published our State of the Nation report, and it shows some really encouraging progress for lung cancer care in England and Wales. Firstly, we’ve seen an increase in the number of patients diagnosed with early-stage disease, more than we’ve ever seen before. So it’s about 40% of patients now being diagnosed with stage 1, 2 disease. This has resulted in an increase in the absolute number of patients who have undergone curative intent treatment options, such as surgery and radical radiotherapy. And we’ve also seen an increase in the proportion of patients having surgical resection for lung cancer. Promisingly, we’re also seeing that survival is continuing to improve in lung cancer. However, there are some challenges that we’re facing. So waiting times continue to be longer than the recommended pathway outlined by the National Optimal Lung Cancer Pathway. And we’re seeing variation in access to treatments. And therefore, we face system-level challenges to try and increase capacity not only for diagnoses but also for curative intent treatment options and that involves not just having more medical professionals who are able to provide those treatments but also the allied healthcare professionals that also help to deliver that care and people such as lung cancer nurse specialists are really important for moving patients through the pathway effectively and efficiently and they can also help to deliver equitable access to these treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
